Natural history and staging of chronic myelogenous leukaemia. Review uri icon

Overview

abstract

  • The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-alpha (IFN-alpha) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-alpha, but achieving a cytogenetic response with IFN-alpha is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.

publication date

  • June 1, 1997

Research

keywords

  • Antineoplastic Agents
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Identity

Scopus Document Identifier

  • 0030756485

PubMed ID

  • 9376664

Additional Document Info

volume

  • 10

issue

  • 2